Register Now: MOUD Training and Member’s Meeting

Monday November 23 

Thank you to those who joined us for a successful part 1 of the MOUD Waiver Training!*

To obtain details on CME claim and instructions on part 2 of the MOUD Waiver Training, please contact Cailey Nickerson: cailey@wsma.org

 

*Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

At the conclusion of this activity participants should be able to:

  1. Screen and identify patients with OUD and define evidence-based treatments.
  2. Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
  3. Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
  4. Explain the process of buprenorphine induction as well as stabilization and maintenance.
  5. Discuss all FDA approved antagonist and agonist medications to treat OUD.
  6. Discuss basic office protocols including medical record documentation and confidentially.
  7. Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
  8. Recognize the importance of obtaining a waiver to begin treating patients with OUD.

COVID-19 Updates

Helpful Links


NEW! “Alaskans must act now to avoid the worst from COVID-19”  Full article here
An op-ed piece written by AK-ACEP Board members, Drs. Nate Peimann, Nick Papacostas, Dave Scordino,  Russ Johanson, Stan Robinson, Leigh Wright, Chris Mickelson, Ben Shelton 

“We’re the directors of Alaska’s emergency rooms. It’s time to shut down nonessential air travel.”
An op-ed piece on the Anchorage Daily News urges Alaska citizens to severely limit travel to the lower 48.

Risk & Evaluation Criteria

The CDC website has a chart to guide evaluation of patients under investigation.

Cases should be reported to the hospital’s infection control department and to the local or state health department.

Testing in the U.S.: More laboratories are coming on line each day, and test turnaround times should improve. View CDC’s map of COVID-19 test availability.